



JOINT WORKING EXECUTIVE SUMMARY

Project Title: Redesign of interstitial lung disease (ILD) service - proof of concept to inform ILD service development locally and regionally.

Project description:

University Hospitals South Manchester(UHSM) provides specialist respiratory services for the North West and houses the Manchester Interstitial lung disease (ILD) hub.

Through service re-design and pathway changes the aim of the project is to improve the quality of patient care, NHS efficiency to provide insight and a potential best practice model to support the wider NHS ILD service design and infrastructure.

Organisations involved:

The University Hospitals South Manchester NHS Foundation Trust, Pennine Acute Hospitals Trust and Roche Products Ltd.

Project approach:

It is proposed the project will run through 4 phases:

1. Mapping of current service to establish baseline.
2. Develop service/pathway re-design proposal.
3. Run Pilot to evaluate impact of service/pathway re-design.
4. Write up and publication of case study.

Expected outcomes:

The outputs of the project will be published as a case study and will be used to inform the development of the service locally and regionally.

Benefits to Patients:

Re-design of the ILD service at UHSM and Pennine NHS Hospital Trusts will improve the quality of care and the service patients receive, reducing delays in referral and improving early diagnosis

Benefit to NHS:

Provide a more efficient service model to allow effective management of the current level of patient demand and to inform development of service both locally and regionally.

Benefits to Roche:

Insights from service re-design and case study could be replicated within the wider NHS supporting other Trusts to build optimal models of care that meets NICE guidelines

The project is limited to support the re-design of services and there will be no assessment of patient outcomes or safety. Treatment choices will not be modified as part of the joint working project. Roche produces one of the two treatment options for IPF patients although this project will not impact treatment decision making.

Resource Breakdown

Roche Products Ltd contribution to the Joint working project is £12,850 to support NHS staff resource required to deliver the project and for publication . The UHSM NHS Foundation Trust estimated contribution to the project is £11,500 and Pennine acute hospitals trust £2,000 based on prorated personnel resource equivalent.

This document has been produced by Roche Products Ltd.